Pfizer is leaving no stone unturned in its efforts to prevent Novo Nordisk from stealing off with Metsera, the weight-loss therapy developer it is hoping to acquire in a deal worth up to $7.3 billion.

Beverly is a writer, editor, and paralegal specializing in personal finance and tax law. She covers personal financial and legal topics, as well as tax breaks, tax preparation software, and tax law ...